Elevance Health, Inc. $ELV Holdings Raised by Danske Bank A S

Key Points

• Danske Bank raised its stake in Elevance Health by 10.6% in Q4 to 127,730 shares (about $44.78 million), and institutional investors now own roughly 89.24% of the stock.
• Elevance reported a quarter beat with $12.58 EPS (vs. $10.74 est.) and revenue of $49.49 billion, and analysts overall rate the stock a "Moderate Buy" with an average target of $384.58 after several firms raised price targets.
• The company announced a quarterly dividend of $1.72 per share (annualized $6.88) with a yield of 1.8%, payable June 25 to holders of record on June 10.

Danske Bank A S raised its stake in shares of Elevance Health, Inc. (NYSE:ELV - Free Report) by 10.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 127,730 shares of the company's stock after buying an additional 12,212 shares during the period. Danske Bank A S owned about 0.06% of Elevance Health worth $44,776,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Physician Wealth Advisors Inc. increased its position in Elevance Health by 331.6% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company's stock worth $26,000 after purchasing an additional 63 shares during the last quarter. Rossby Financial LCC raised its stake in shares of Elevance Health by 110.0% during the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company's stock worth $28,000 after purchasing an additional 44 shares in the last quarter. Activest Wealth Management lifted its holdings in shares of Elevance Health by 66.7% during the 3rd quarter. Activest Wealth Management now owns 85 shares of the company's stock valued at $27,000 after buying an additional 34 shares during the last quarter. Motco grew its stake in shares of Elevance Health by 334.8% in the 3rd quarter. Motco now owns 100 shares of the company's stock valued at $32,000 after buying an additional 77 shares in the last quarter. Finally, ORG Partners LLC grew its stake in shares of Elevance Health by 120.4% in the 4th quarter. ORG Partners LLC now owns 108 shares of the company's stock valued at $38,000 after buying an additional 59 shares in the last quarter. 89.24% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Barclays raised their price objective on shares of Elevance Health from $393.00 to $408.00 and gave the company an "overweight" rating in a research report on Friday, April 24th. Wolfe Research set a $425.00 price target on shares of Elevance Health and gave the stock an "outperform" rating in a research note on Thursday, January 8th. Sanford C. Bernstein raised their price target on shares of Elevance Health from $384.00 to $424.00 and gave the company an "outperform" rating in a report on Friday, April 24th. Jefferies Financial Group reduced their price objective on shares of Elevance Health from $395.00 to $391.00 and set a "buy" rating for the company in a research note on Monday, April 20th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Elevance Health from $397.00 to $411.00 and gave the stock an "overweight" rating in a report on Tuesday. Thirteen investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat.com, Elevance Health currently has an average rating of "Moderate Buy" and an average target price of $384.58.

Elevance Health Stock Performance

NYSE:ELV opened at $372.78 on Friday. The firm has a market capitalization of $80.95 billion, a PE ratio of 15.86, a PEG ratio of 2.14 and a beta of 0.66. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $424.24. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70. The firm's fifty day simple moving average is $310.69 and its 200 day simple moving average is $331.90.

Elevance Health (NYSE:ELV - Get Free Report) last released its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, topping analysts' consensus estimates of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The firm had revenue of $49.49 billion during the quarter, compared to analyst estimates of $48.21 billion. During the same quarter in the previous year, the business earned $11.97 EPS. The business's revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, sell-side analysts anticipate that Elevance Health, Inc. will post 26.79 EPS for the current year.

Elevance Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be given a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a dividend yield of 1.8%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health's payout ratio is currently 29.26%.

Elevance Health Profile

Elevance Health, Inc NYSE: ELV is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company's strategic focus on integrated health care and benefit delivery.

Elevance's core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.